Table 1.
First authors | Year | Country | Study design | Treatment line | Tailored determinant | Patients (tailored/empiric) | Eradication regime | Eradication rate of TT | Eradication rate of ET | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Tailored regimens | Empiric regimens | ITT | PP | ITT | PP | |||||||
Cha | 2021 | Korea | RCT | 1 | DPO-PCR | 182/178 | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days CLA-r: BIS 300 mg QID + MET 500 mg TID + TET 500 mg QID + RAB 20 mg BID, 7 days |
BIS 300 mg QID + MET 500 mg TID + TET 500 mg QID + RAB 20 mg BID, 7 days | 66.3% (118/178) | 81.4% (118/145) | 78.0% (142/182) | 88.8% (142/160) |
Choi | 2021 | Korea | RCT | 1 | DPO-PCR | 110/107 | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + LAN 30 mg BID, 14 days CLA-r: BIS 300 mg QID + MET 500 mg BID + TET 500 mg QID + LAN 30 mg BID, 10 days |
AMO 1000 mg BID + MET 500 mg BID + CLA 500 mg BID + LAN 30 mg BID, 10 days | 82.7% (91/110) | 90.1% (91/101) | 82.2% (88/107) | 91.6% (87/95) |
Cho | 2021 | Korea | RCT | 1 | DPO-PCR | 141/141 | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + PAN 40 mg BID, 7 days CLA-r: BIS 300 mg QID + MET 500 mg TID + TET 500 mg QID + PAN 40 mg BID, 7 days |
BIS 600 mg BID + AMO 1000 mg BID + MET 750 mg BID + PAN 40 mg BID, 14 days | 80.9% (114/141) | 89.0% (113/127) | 85.8% (121/141) | 93.5% (116/124) |
Delchier | 2020 | France | RCT | 1 and 2 | GenoType HelicoDR® PCR | 266/260 | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + PPI BID, 7 days CLA-r + LEV-s: AMO 1000 mg BID + LEV 250 mg BID + PPI BID, 10 days CLA-r + LEV-r: AMO 1000 mg BID + MET 500 mg BID + PPI BID, 14 days (OME 20 mg BID or ESO 20 mg BID or LAN 30 mg BID or PAN 40 mg BID or RAB 20 mg BID) |
First line: AMO 1000 mg BID + CLA 500 mg BID + PPI BID, 7 days Second line: AMO 1000 mg BID + MET 500 mg BID + PPI BID, 14 days (OME 20 mg BID or ESO 20 mg BID or LAN 30 mg BID or PAN 40 mg BID or RAB 20 mg BID) |
85.5% (177/207) | 86.5% (173/200) | 73.1% (152/208) | 74.4% (151/203) |
Furuta | 2007 | Japan | RCT | 1 | PCR | 150/150 | CLA-s: AMO 500 mg TID + CLA 200 mg TID + LAN 15 mg/30 mg BID (According to CYP2C19), 7 days CLA-r: AMO 500 mg QID + LAN 15 mg/30 mg BID (According to CYP2C19), 14 days |
AMO 750 mg BID + CLA 400 mg BID + LAN 30 mg BID, 7 days | 96.0% (144/150) | 96.6% (144/149) | 70.0% (105/150) | 72.9% (105/144) |
Hsieh | 2022 | China | RCT | 1 | PCR-RLFP | 91/91 | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days CLA-r, LEV-s: AMO 1000 mg BID + LEV 500 mg QD + RAB 20 mg BID, 7 days CLA-r, LEV-r: AMO 1000 mg BID (14 days) + CLA 500 mg BID (7 days) + MET 500 mg BID (7 days) or AMO 1000 mg QID + RAB 20 mg QID, 14 days |
AMO 750 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days | 89.0% (81/99) | 91.0% (81/89) | 75.8% (69/91) | 79.3% (69/87) |
Kawai | 2008 | Japan | RCT | 1 | PCR | 35/35 | CLA-s: AMO 750 mg BID + CAM 400 mg BID + LAP 30 mg BID, 7 days CLA-r/mixed infections: AMO 750 mg BID + MET 250 mg BID + RAB 10 mg BID, 7 days |
AMO 750 mg BID + CAM 400 mg BID + LAN 30 mg BID, 7 days | 94.3% (33/35) | 94.3% (33/35) | 71.4% (25/35) | 78.1% (25/32) |
Kim | 2020 | Korea | RCT | 1 | DPO-PCR | 36/36 | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + ESO 40 mg BID, 10 days CLA-r: BIS 300 mg BID + TET 500 mg QID + MET 500 mg TID + ESO 40 mg BID, 10 days |
AMO 1000 mg BID + CLA 500 mg BID + ESO 40 mg BID, 10 days | 88.9% (32/36) | 97.0% (32/33) | 75.0% (27/36) | 81.8% (27/33) |
Kim | 2022 | Korea | RCT | 1 | DPO-PCR | 145/145 | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 14 days CLA-r: TET 1000 mg QID + MET 500 mg TID + BIS 120 mg QID + RAB 20 mg BID, 14 days |
AMO 1000 mg BID + CLA 500 mg BID + MET 500 mg + RAB 20 mg BID, 14 days | 85.5% (124/145) | 94.6% (122/129) | 82.8% (120/145) | 88.6% (117/132) |
Lee | 2013 | Korea | RCT | 1 | DPO-PCR | 218/616 | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days CLA-r: AMO 1000 mg BID + MET 500 mg TID + RAB 20 mg BID, 7 days |
APC: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days APM: AMO 1000 mg BID + MET TID + RAB 20 mg BID, 7 days |
80.7% (176/218) | 91.2% (176/193) | 70.3% (433/616) | 77.5% (433/559) |
Liou | 2018 | China | RCT | 3 and more | PCR | 205/205 | (EPZ 40 mg BID + AMP 1000 mg BID), 7 days + (EPZ 40 mg BID + MET 500 mg BID + LEV 250 mg/CLA 500 mg/TET 500 mg BID) (According to genotypic resistance), 7 days | (EPZ 40 mg BID + AMP 1000 mg BID), 7 days + (EPZ 40 mg BID + MET 500 mg BID + LEV 250 mg/CLA 500 mg/TET 500 mg BID), 7 days | 78.0% (160/205) | 78.4% (156/199) | 72.2% (148/205) | 74.4% (145/195) |
Ong | 2019 | Korea | RCT | 1 | PCR | 201/196 | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + LAN 30 mg BID, 14 days CLA-r: AMO 1000 mg BID + MET 500 mg BID + LAN 30 mg BID, 14 days |
AMO 1000 mg BID + CLA 500 mg BID + MET 500 mg BID + LAN 30 mg BID, 14 days | 81.6% (164/201) | 86.5% (154/178) | 86.2% (169/196) | 90.2% (157/174) |
AMO, amoxicillin; APM, amoxicillin + rabeprazole + metronidazole; APM, amoxicillin + rabeprazole + clarithromycin; BID, two times a day; BIS, bismuth; CLA, clarithromycin; CLA-r, clarithromycin resistant; CLA-s, clarithromycin sensitive; DPO-PCR, dual priming oligonucleotide polymerase chain reaction; EPZ, esomeprazole; ET, empirical therapy; FUR, furazolidone; LAN, lansoprazole; LEV, levofloxacin; LEV-r, levofloxacin resistant; LEV-s, levofloxacin sensitive; MET, metronidazole; MET-r, metronidazole resistant; MET-s, metronidazole sensitive; PCR-RLFP, polymerase chain reaction-restriction fragment length polymorphism; PPI, proton-pump inhibitor; QD, once a day; QID, four times a day; RAB, rabeprazole; RCT, randomized control trial; TET, tetracycline; TID, three times a day; TT, tailored therapy.